Bridges Investment Management Inc. Purchases Shares of 6,069 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bridges Investment Management Inc. acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,069 shares of the medical equipment provider’s stock, valued at approximately $487,000.

A number of other hedge funds have also made changes to their positions in LNTH. UMB Bank n.a. boosted its position in Lantheus by 161.4% during the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 247 shares during the period. GAMMA Investing LLC lifted its stake in shares of Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 208 shares in the last quarter. Principal Securities Inc. acquired a new stake in shares of Lantheus in the fourth quarter valued at about $28,000. Fidelis Capital Partners LLC acquired a new position in shares of Lantheus during the first quarter worth $34,000. Finally, FinTrust Capital Advisors LLC boosted its stake in shares of Lantheus by 53.6% in the first quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 232 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on LNTH. Leerink Partners lifted their price target on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. B. Riley lifted their target price on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. JMP Securities reduced their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Finally, Truist Financial cut their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $126.00.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $110.05 on Friday. The business has a 50 day simple moving average of $105.51 and a 200-day simple moving average of $84.24. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The company has a market capitalization of $7.63 billion, a price-to-earnings ratio of 16.80 and a beta of 0.50. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same period last year, the company posted $1.40 earnings per share. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. As a group, equities research analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the sale, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. The disclosure for this sale can be found here. Insiders have sold a total of 40,852 shares of company stock worth $3,922,001 over the last quarter. 1.50% of the stock is owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.